Invasive and noninvasive correlations of B-type natriuretic peptide in patients with heart failure due to chagas cardiomyopathy

Congestive Heart Failure

Volumn 14, Issue 3, 2008, Pages 121-126

  Vilas Boas, Fábio ^a   Feitosa, Gilson Soares ^a   Soares, Milena B P ^b   Pinho Filho, Joel Alves ^a   Nascimento, Thais ^a   Barojas, Marcos M ^a   Andrade, Marcus V S ^a   Ribeiro dos Santos, Ricardo ^b   Bocchi, Edimar ^c  

^a HOSPITAL SANTA IZABEL   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ARTICLE; BLOOD; CASE CONTROL STUDY; CHAGAS DISEASE; DIASTOLE; EXERCISE TOLERANCE; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEMODYNAMICS; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SYSTOLE;

CASE-CONTROL STUDIES; CHAGAS CARDIOMYOPATHY; DIASTOLE; EXERCISE TOLERANCE; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SYSTOLE;

EID: 53049086308     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.08166.x     Document Type: Article

References (34)

1. Redfield MM. Heart failure - an epidemic of uncertain proportions. N Engl J Med. 2002;347:1442-1444.
2. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas' disease control in Latin America: a review. Mem Inst Oswaldo Cruz. 2002;97(5):603-612.
3. Shulman IA, Appleman MD, Saxena S, et al. Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion. 1997;37:727-731.
4. Pontes-de-Carvalho L, Santana CC, Soares MB, et al. Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. J Autoimmun. 2002;18(2):131-138.
5. Cunha-Neto E, Duranti M, Gruber A, et al. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci U S A. 1995;92:3541-3545.
6. Rassi A Jr, Rassi A, Little WC, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006;355:799-808.
7. Garcia S, Ramos CO, Senra JF, et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother. 2005;49:1521-1528.
8. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. A nonrandomized trial. Ann Intern Med. 2006;144:724-734.
9. Maisel AS, Krishnaswamy P, Nowak RM, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
10. Berger R, Huelsman M, Stecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2391-2396.
11. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-654.
12. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000;2:198-205.
13. Villacorta H, Duarte A, Duarte NM, et al. The role of B-type natriuretic peptide in the diagnosis of congestive heart failure patients presenting to an emergency department with dyspnea. Arq Bras Cardiol. 2002;79:569-572.
14. Melo RB, Parente GB, Victor EG. Measurement of human brain natriuretic. peptide in patients with Chagas' disease. Arq Bras Cardiol. 2005;84:137-140.
15. Talvani A, Rocha MOC, Cogan J, et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz. 2004;99:645-649.
16. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
17. Stewart WJ, Rodkey SM, Gunawardena S, et al. Left ventricular volume calculation with integrated backscatter from echocardiography. J Am Soc Echocardiogr. 1993;6:553-563.
18. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure. 1987;3:198-209.
19. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA. 1993;270:1702-1707.
20. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The six minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919-923.
21. Cheng V, Kazanegra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-391.
22. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-422.
23. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367-374.
24. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343(8895):440-444.
25. Ribeiro AL, dos Reis AM, Barros MV, et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet. 2002;360:461-462.
26. Rassi A Jr, Rassi A, Little WC. Chagas' heart disease. Clin Cardiol. 2000;23:883-889.
27. Marques DS, Canesin MF, Barutta Júnior F, et al. Evaluation of asymptomatic patients with chronic Chagas disease through ambulatory electrocardiogram, echocardiogram and B-type natriuretic peptide analyses. Arq Bras Cardiol. 2006;87:336-343.
28. Mariano-Goulart D, Eberle MC, Boudousq V, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail. 2003;5:481-488.
29. Heringer-Walther S, Moreira MC, Wessel N, et al. Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptide. Heart. 2005;91(3):385-387.
30. Ribeiro AL, Teixeira MM, Reis AM, et al. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int J Cardiol. 2006;109(1):34-40.
31. Tepper D. Frontiers in congestive heart failure: anemia is associated with worse symptoms, greater impairment in functional capacity, and a significant increase in mortality in patients with advanced heart failure. Congest Heart Fail. 2002;8:235-236.
32. Mocelin AO, Issa VS, Bacal F, et al. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas' heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2005;7(5):869-873.
33. Pinto Dias JC. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med. 2006;144(10):772-774.
34. Wieczorek SJ, Hager D, Barry MB, et al. Correlation of B-type natriuretic peptide level to 6-min walk test performance in patients with left ventricular systolic dysfunction. Clin Chim Acta. 2003;328:87-90.